Regulation of CCL18 by Corticosteroids in Severe Asthma
Study Details
Study Description
Brief Summary
The majority of asthmatic patients are well controlled by inhaled corticosteroid treatment, however some severe asthma resist this treatment. CCL18 is a target gene for corticosteroids and its dysfunction may correlate with phenotypes of asthma.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| non asthmatic subjects
|
|
| intermittent asthmatics
|
|
| severe asthmatics sensitive to corticosteroids
|
|
| severe asthmatics resistant to corticosteroids
|
|
| moderate asthmatics
|
Outcome Measures
Primary Outcome Measures
- Correlation between CCL18 rate and asthma phenotypes by elisa test [Baseline: one session]
Eligibility Criteria
Criteria
Inclusion Criteria:
- control subjects =
-
non-atopic and non-smoking
-
cutting to negative pneumoallergens,
-
Total IgE levels less than 100 ku / L
-
no clinical history of asthma
-
without background treatment
- patients with intermittent asthma =
-
being asymptomatic between asthma attacks,
-
with symptoms less than once a week
-
having a forced expiratory volume per second (FEV1) of at least 80% of the theoretical.
-
treated by ß2 mimetics on demand and will not have inhaled corticosteroids.
- severe asthma insensitive to corticosteroid therapy =
-
continuous or nearly continuous treatment with oral corticosteroids (≥ 50% of the year) / or treatment with IC ≥ 1500 microg beclomethasone dipropionate equivalent (BDP)] airway obstruction fixed with FEV1 ranging from less than 15% after 7 days of oral corticosteroid therapy to 40 mg / day of prednisolone;
-
Followed at the immunoallergology pneumology consultation for at least 1 year will be recruited.
- Severe corticosensitive asthma = continuous or near continuous treatment with oral corticosteroids (≥ 50% of the year) / or treatment with IC ≥ 1500 microg beclomethasone dipropionate equivalent (BDP)]
-
reversibility of FEV1 after treatment with oral corticosteroids.
-
Followed at the immunoallergology pneumology consultation for at least 1 year will be recruited.
- controlled moderate asthma treated with inhaled corticosteroids <1500μg equivalent of beclomethasone dipropionate and with: ß2 long-acting mimetics (or anti-leukotriene, or theophylline) for at least 6 months.
Exclusion Criteria:
-
existence of a chronic inflammatory pathology other than asthma
-
active smoking
-
pregnant or lactating women
-
have received oral corticosteroid treatment in the previous 3 weeks,
-
have received non-steroidal anti-inflammatory drugs (NSAIDs) in the previous 2 weeks.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hôpital Calmette, CHRU | Lille | France |
Sponsors and Collaborators
- University Hospital, Lille
Investigators
- Principal Investigator: Benoit Wallaert, MD, PhD, University Hospital, Lille
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2008/0813
- 2008-A00370-55